Lexington, Mass., USA - December 2, 2010, Lexington, Mass., USA - Synta Pharmaceuticals announced that Amar Singh has joined the company as senior vice president of business and commercial development and Iman El-Hariry has been appointed vice president of clinical research.
Article continues below
Mr. Singh joins Synta from Spectrum Pharmaceuticals, where he most recently served as Chief Operating Officer, and previously as SVP and Chief Commercial Officer. At Spectrum, he led the commercial and business development teams responsible for the successful re-launch of Zevalin and completed major partnerships for Zevalin (Cell Therapeutics) and Belinostat (TopoTarget).
Prior to joining Spectrum, Mr. Singh was VP and Chief Commercial Officer at Novacea where he was responsible for securing major partnerships for the company’s lead compound, Asentar. Prior to Novacea, Mr. Singh led the launch of the proprietary division of American Pharmaceutical Partners-Abraxis Oncology and provided leadership in all aspects of commercial, and strategic development of the company’s flagship product, Abraxane.
Prior to Abraxis, Mr. Singh held multiple leadership positions in the oncology franchise at Hoffman-La Roche, where he led the launches of several oncology and supportive care products including Xeloda and Kytril.
Mr. Singh holds an MBA from the Stern School of Business at New York University and a BA from the University of North Carolina.
Mr. El-Hariry is an oncologist with 13 years global pharmaceutical oncology development experience. She joins Synta from Astellas Pharma where she served as Astellas’ first Global Head of Oncology.
Prior to Astellas, Dr. El-Hariry served in key clinical development roles at GlaxoSmithKline (GSK), where she oversaw over 50 Phase 1 through Phase 4 clinical trials, led multiple European and U.S. regulatory agency submissions resulting in successful product approvals, and initiated and led a broad network of academic and medical community collaborations in support of GSK oncology drug candidates. ■